Documentos relacionados

1. Physcion inhibition of CYP2C9, 2D6 and 3A4 in human liver microsomes.
2. Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors .
3. Methysticin Acts as a Mechanism-Based Inactivator of Cytochrome P450 2C9.
4. Cytochrome P450: genotype to phenotype.
5. Mechanistic Study of Icaritin-Induced Inactivation of Cytochrome P450 2C9.
6. Prediction of Cytochrome P450 Inhibition Using a Deep Learning Approach and Substructure Pattern Recognition.
7. Modeled Hepatic/Plasma Exposures of Fluvastatin Prescribed Alone in Subjects with Impaired Cytochrome P450 2C9*3 as One of Possible Determinant Factors Likely Associated with Hepatic Toxicity Reported in a Japanese Adverse Event Database.
8. Effect of deglucuronidation on the results of the Basel phenotyping cocktail.
9. Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers.
10. Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis.